Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC) and relapsed anaplastic large cell lymphoma (Passerini et al., 2014, JNCI). It inhibits the action of the EML4-ALK fusion protein as an inhibitor (Lei et al., 2022, Oncol Lett).
DISCLAIMER: THIS WEBSITE DOES NOT PROVIDE MEDICAL NOR FINANCIAL ADVICE.
Pillar Health Pte. Ltd. (UEN 202310045D) does not provide any financial nor medical advice.
The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.
No material on this site is intended to be a substitute for professional financial advice. Always seek the advice of your financial advisor with any questions you may have regarding any financial related questions, and never disregard professional financial advice because of something you have read on this website.
You have reviewed and hereby agree to the Terms of Use for accessing this Website.
You hereby consent to the collection, use and disclosure of our Personal Data below by Pillar Health Pte Ltd on the terms and conditions set out in the Personal Data Protection Policy.
